文献速递临床试验与 GCP

宫内灌注甲哌卡因与安慰剂用于宫内节育器放置镇痛:一项随机临床试验

Intrauterine Mepivacaine Instillation vs Placebo for Pain During IUD Placement: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

这项多中心双盲随机对照试验纳入370名未产女性,比较宫内灌注甲哌卡因与生理盐水对宫内节育器放置疼痛的影响。

要点

  • 宫内灌注甲哌卡因可显著降低未产女性宫内节育器放置时的疼痛评分。
  • 甲哌卡因组疼痛耐受比例98.3%,高于安慰剂组的91.4%,NNT为15。
  • 该镇痛方法简单,在放置前2分钟通过宫腔超声导管注入即可。

核心结论

  • 与安慰剂生理盐水相比,宫内灌注10 mL甲哌卡因(20 mg/mL)可显著减轻宫内节育器放置时的疼痛并改善耐受性。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照试验,在瑞典11家门诊妇科、孕产妇健康和青年诊所开展,时间2021年5月至2024年6月。
  • 共随机370名未产女性(18-31岁),1:1分组,每组185人,分别接受宫内灌注10 mL甲哌卡因(20 mg/mL)或生理盐水(9 mg/mL)。
  • 主要结局为临床医生调整的放置期间疼痛评分(100 mm视觉模拟量表),主要分析纳入所有有主要结局数据的随机参与者。

主要发现

  • 甲哌卡因组175人中有172人(98.3%)报告疼痛可耐受,安慰剂组174人中有159人(91.4%)报告可耐受,相对风险1.08(95%CI 1.02-1.13),NNT为15(95%CI 9-43)。

临床怎么用

  • 对于选择小直径放置管宫内节育器(左炔诺孕酮19.5 mg、13.5 mg或铜宫内节育器)的未产女性,可考虑在放置前2分钟宫内灌注10 mL甲哌卡因(20 mg/mL)以减轻疼痛。

局限性

  • 研究仅纳入18-31岁未产女性,使用特定小直径放置管宫内节育器,结果外推至其他人群或节育器类型需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Concern about pain during intrauterine device (IUD) placement is common and reduces selection of an IUD. Reducing procedure-related pain may support informed contraceptive decision-making and patient autonomy and has also been associated with improved patient satisfaction and procedural experience. OBJECTIVE: To determine whether intrauterine instillation of mepivacaine reduces pain during IUD placement in nulliparous individuals. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, randomized, placebo-controlled trial conducted at 11 outpatient gynecology, maternal health, and youth clinics in Sweden from May 2021 through June 2024. Nulliparous individuals aged 18 to 31 years opting for IUDs with smaller-diameter placement tubes (levonorgestrel 19.5 mg, 13.5 mg, or copper IUD) were eligible. Key exclusion criteria included ongoing pregnancy, IUD replacement, pelvic infection, and allergy to local anesthetics. A total of 370 participants were randomized. INTERVENTIONS: Participants were randomly assigned (1:1) (185 per group) to intrauterine instillation of 10 mL of mepivacaine (20 mg/mL) or sodium chloride (9 mg/mL) via a hydrosonography catheter 2 minutes before IUD placement. Participants, clinicians, and outcome assessors were blinded to treatment allocation. MAIN OUTCOMES AND MEASURES: The primary outcome was clinician-adjusted difference in pain scores during IUD placement, measured on a 100-mm visual analog scale. The primary analysis included all randomized participants with available primary outcome data. Prespecified secondary analyses included tolerability and overall experience. RESULTS: A total of 370 participants were randomized. Mean age was 21.7 (SD, 3.0) years in the mepivacaine group and 21.7 (SD, 2.9) years in the placebo group. Mean pain score during IUD placement was 43.8 mm (SD, 24.7) in the mepivacaine group and 58.6 mm (SD, 21.5) in the placebo group (mean difference, 14.8 mm [95% CI, 10.0-19.6]; P < .001). Adjustment for individual clinician yielded similar results (mean difference, 14.2 mm [95% CI, 9.7-18.6]; P < .001). Tolerable pain was reported by 172 of 175 participants (98.3%) in the mepivacaine group and 159 of 174 (91.4%) in the placebo group (relative risk, 1.08 [95% CI, 1.02-1.13]; NNT, 15 [95% CI, 9-43]). CONCLUSIONS AND RELEVANCE: Intrauterine instillation of 10 mL of mepivacaine (20 mg/mL) significantly reduced pain and improved tolerability during IUD placement compared with instillation of placebo saline. TRIAL REGISTRATION: EudraCT Identifier: 2020-002271-36.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Elgemark K, Envall N, Kopp Kallner H, et al. Intrauterine Mepivacaine Instillation vs Placebo for Pain During IUD Placement: A Randomized Clinical Trial. JAMA. 2026. PMID: 42752558. doi:10.1001/jama.2026.14217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。